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ABSTRACT
The efficacy and safety of budesonide nasal powder (Rhinocort 
Turbuhaler(R)) in seasonal allergic rhinitis when given only at 
the onset of symptoms during the pollen season or when also
given before the pollen season, were compared. The study 
was carried out in 364 patients from 14 centres in Italy as 
a randomized, double-blind, parallel-group, placebo-
controlled comparison of five alternative treatment regimens 
given for 4 weeks during the pre-pollen and early pollen sea-
son (PPS) and for 6 weeks during the pollen season (PS). It was
concluded that either 200μg or 400μg of budesonide given
once daily PPS provides significant control of symptoms expe-
rienced during PPS. The 400μg dose, however, also provides
additional prophylactic protection against symptoms during 
early PS. When the pollen season is established, the dose of
budesonide may be reduced to 200μg.
Key words: allergic, budesonide, inflammation, prophylac-
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INTRODUCTION
Allergic rhinitis, the most common form of atopic disease, is 
characterized by inflammation of the nasal mucosa, resulting in 
symptoms such as sneezing, hypersecretion and nasal block-
age. Cytology of the nasal mucosa in such patients indicates 
that eosinophils, neutrophils and basophils are present.' An 
influx of these cells accompanies the late reaction in response
to nasal allergen challenge and there is a strong correlation 
between the number of basophils and the level of histamine. 
There is also a correlation between the number of eosinophils 
and the level of eosinophil major basic protein, suggesting that
the inflammatory cells not only enter the nose, but also degran-
ulate,2,3 thereby releasing inflammatory mediators.
 Topical glucoconccosteroids such as budesonide have been 
shown to be highly effective and safe for the treatment of aller-
gic rhinitis, providing at least comparable efficacy to that of oral
steroids, with reduced systemic side-effects.4 If patients are 
treated for 1 week with budesonide during a pollen-free period, 
the immediate response provoked by subsequent challenge is 
markedly reduced,5 probably because topical corticosteroids
improve the nasal epithelial barrier and inhibit the influx of 
inflammatory cells in response to allergens.6 Budesonide has 
been shown to reduce the influx of eosinophils and the level of 
eosinophilic cationic protein (ECP),7 as well as tissue levels of
histamine.8 This has also been demonstrated with fluticasone 
propionate, and a statistical correlation was found between the 
degree of improvement in nasal reactivity to histamine and the 
reduction in ECP levels in the nasal lavages.9
 Inhaled budesonide is capable of inhibiting the late response 
to allergen challenge, even when it is given immediately prior to 
challenge, whereas the immediate response is only inhibited 
after some days of pre-treatment.10 These results indicate that
steroids are acting on different mechanisms according to treat-
ment duration. Some markers of nasal mucosa) inflammation 
indicate that the inflammatory process may be active during the 
allergy season before any symptoms appear,11,12 so it is proba-
bly better to pre-treat patients for some weeks prior to the main 
pollen season. With this in mind, the aim of this study was to 
compare the efficacy of budesonide administered for 1 month
before (i. e. prophylactically) as well as during the pollen sea-
son, with that administered only during the pollen season.
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METHODS
Patients
Patients aged 15-65 years were eligible for the study if they had 
a history of seasonal allergic rhinitis (to grass pollen) of at least 
1 year and fulfilled the following additional criteria: no infec-
tious, atrophic or perennial rhinitis; no acute or chronic sinusitis; 
no nasal polyposis; no asthma requiring corticosteroid treat-
ment; no systemic corticosteroid therapy during the previous 
month; no current immunotherapy; no pregnancy or lactation. 
They were recruited from 14 clinics throughout Italy and entered 
the study on suitable starting dates between March and May
1992, which were estimated to be in the pre-pollen season 
(PPS) for each region according to the mean pollen count data 
previously reported by the Italian Aeroallergen Network.13
Study design and assessments
The study was conducted over a 10 week period; 4 weeks before 
the expected pollen season and 6 weeks during the pollen sea-
son. Patients attended the clinic on four occasions: at entry (visit 
1), after 4 weeks (visit 2), 7 weeks (visit 3) and 10 weeks (visit 4).
At entry, their demographic details were recorded and a skin 
prick test was performed for allergy assessment, if one had not 
been done recently.
 Patients were then randomly allocated to one of five parallel 
treatment regimens. Treatment was administered in a double-
blind fashion using identical nasal inhalers (Turbuhaler(R)) that
contained either ladose (placebo) or budesonide, 100μg/dose
or 200μg/dose delivered as a pure powder.14 Patients were
treated for 4 weeks before the expected (pre-) pollen season 
(PPS) and for 6 weeks during the pollen season (PS; Table 1).
  Patients were asked to take their treatment (one dose to each 
nostril) at the same time each morning and were permitted 
to take 'rescue' antihistamine therapy, if their symptoms persisted
despite regular intake of their study drug. Their use of extra med-
ication was to be recorded in a daily diary card, as were the 
symptoms of blocked nose, runny nose and sneezing. The symp-
Table 1. Treatment regimens given during the pre-pollen and early 
pollen season (PPS) and during the pollen season (PS)
toms were rated on a scale from zero to 3; (0=no symptoms; 
1=mild symptoms, present but not troublesome; 2=moderate 
symptoms, frequently troublesome but not sufficient to interfere 
with normal daily activity or night-time sleep; 3=severe symp-
toms, sufficiently troublesome to interfere with normal daily activ-
ity or night-time sleep). At subsequent visits, patients were asked 
whether their treatment had controlled their symptoms.
Pollen counts
Data on daily pollen counts were obtained from the Italian 
Aeroallergen Network, which uses the Burkard volumetric trap 
method for pollen collection at sampling sites all over Italy
(Fig. 1). The number of grass pollen grains were reported as the 
number of grains/cubic meter of air, and the total number of
patient exposure days (study duration days × number of cen-
tres) to the different pollen levels of Graminaceae and Parietaria 
are shown in Fig. 2.
Statistical methods
Data were analyzed using an 'all patients treated' approach, in 
which patients had to have taken at least one dose of medica-
tion and have at least 3 days of diary data. Unlike the 'per pro-
Fig. 1 Pollen sampling sites used by the Italian Aeroallergen Network.
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Fig. 2 Total exposure to Graminaceae
tocol' approach, this analysis included data from the diary cards 
for days on which additional decongestants et cetera had been
taken by the patients. It was evident from the data that such days 
represented symptomatic days and should thus be included in 
the analysis.
 The primary efficacy variables were the three nasal symptoms 
recorded in the daily diary and the patient's assessment of the 
study treatment at the end of the study. For each patient, mean
values were calculated for individual symptom scores as well as 
a total nasal symptom score for the 4 weeks pre-pollen season, 
individual weeks 1, 2 and 3 of the pollen season and weeks 
4-6 combined. Analysis of covariance (ANCOVA) was used to test
for differences among the five treatment groups (checking for 
parallelism) and, if the overall treatment difference was signifi-
cant, pairwise comparisons of the treatment groups were inves-
tigated to find out where the differences were. The mean
Graminaceae counts corresponding to each patient's treatment 
period were included in the analysis as a covariate, to adjust for 
any biases that might have resulted from group differences in 
mean pollen levels. To investigate the effect of treatment in rela-
tion to the level of pollen, the pollen count interval method of 
Wilkinson and Taudorf15 was used. Each patient's daily pollen 
level was the corresponding level of Graminaceae, Parietaria, 
or both, according to the patient's sensitivity. The range of
pollen counts was divided as closely as possible into quartiles so 
that each of the four intervals contained a similar number of 
days. This was done for PPS and PS. The total symptom scores 
were analyzed for each pollen interval using analysis of variance 
(ANOVA) .
 The patient's own assessment of treatment recorded at visits 
2, 3 and 4 was compared for the five treatment groups using 
the Kruskal-Wallis one-way ANOVA by ranks. When the test 
resulted in significance, pairwise comparisons of the treatment 
groups were made.16
 Antihistamine consumption was calculated as the number of 
days per week on which antihistamines were taken. This was then
compared across the treatments for the PPS and the PS, using 
ANCOVA (including mean Graminaceae counts as a covariate).
RESULTS
Patients included
A total of 364 patients were randomized to study treatment, 219 
males and 145 females with a mean age of 30.7 years (range 
14-67 years). All had a history of at least one season of grass 
pollen-induced allergic rhinitis and 58% of the patients had had
rhinitis for more than 5 years. Skin prick tests indicated that 247 
patients (68%) were positive to Graminaceae, 32 (9%) to 
Parietaria and 85 (23%) were positive to both Graminaceae 
and Parietaria.
In general, the five treatment groups were comparable ini-
tially, although there were more females in groups C and D.
Demographic and disease status details are summarized for
each treatment group in Table 2.
Efficacy
Data were available from 345 patients for an 'all patients 
treated' analysis. The remaining 19 recruited patients were 
exclud d from the analysis due to paucity of diary card data (17 
patients) or no treatment (2 patients). Mean daily symptom 
cores for sneezing, blocked nose and nasal secretion are pre-
sented in Table 3. During the PPS, significant treatment differ-
enc s were detected for sneezing (P=0.001) and nasal 
secr tion (P=0.0001). Pairwise comparisons of the treatment
groups indicated that both sneezing and nasal secretion were
significantly lower during treatment with 400μg or 200μg
budesonide compared with the placebo. No significant differ-
ences were noted for blocked nose. During the PS, significant 
treatment differences were detected during the first week only for 
nasal secretion (P=0.0037). Pairwise comparisons indicated
Table2. Demographic and disease details
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Table 3. Mean daily symptom scores (adjusted for pollen level)
PPS, pre-pollen and early pollen season; PS, pollen season.
Fig. 3 Mean total daily symptoms for each treatment group during 
each treatment period. The mean pollen level for each treatment 
period is boxed. PPS, pre-pollen season and early pollen season; PS, 
pollen season.
that petients treated with 400μg budesonide during PPS were
significantly better controlled than those treated with placebo 
during PPS and during the first week of PS, irrespective of treat-
ment given during PS.
Fig. 4 Mean total symptom scores presented according to quartile 
pollen levels during (a) pre-pollen season and (b) pollen season.
 Mean total daily symptom scores are shown in Fig. 3 for each 
treatment group across each treatment period. The means have
been adjusted for pollen levels on an individual patient basis. 
Mean pollen levels for the group during each treatment period
are also indicated in Fig. 3 under the appropriate time interval. 
During the pre-pollen period, significant treatment differences
were detected using ANCOVA (P=0.0003). Pairwise comparisons 
indicated that the total symptom score was significantly lower
during treatment with 200μg or 400μg budesonide compared
with the placebo. During the PS, a significant treatment differ-
ence was detected during the first week only, with evidence that
400μg budesonide was significantly more effective than the
placebo in controlling symptoms. Mean total symptom scores 
are presented according to quartile pollen levels for PPS and PS
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in Figs 4a and 4b, respectively. At pollen levels of up to 10 
grainsIm3 air during PPS, total symptom scores were signifi-
cantly loweron budesonide 400μg compared with the placebo.
At levels of 10-50 grains/m3 air, symptoms were significantly
lower on both 200μg and 400μg budesonide compared
with the placebo, while at levels of>50 grains/m3 air, only the
400μg dose of budesonide was significantly better than the
placebo. During the entire PS, where all treatments were active,
no significant difference was detected between 200μg and
400μg budesonide in terms of total symptom control at any of
the pollen levels.
Patient assessment
When asked at the clinic about their symptom control, patients
who had taken either 200μg or 400μg budesonide PPS
reported significantly better symptom control than those who 
had taken the placebo (P=0.0001) and they also consumed 
significantly less antihistamine (P=0.03). During PS, no differ-
ence in symptom control and no difference in anthistamine con-
sumption were noted between the two doses of budesonide.
Tolerability
Safety profiles were similar for all groups, with adverse events 
being generally mild and well-tolerated. Three patients discon-
tinued study treatment due to an adverse event. During PPS, one
patient discontinued treatment with 200μg budesonide at his
own request due to moderate pen-orbital monolateral oedema
and one patient discontinued budesonide 400μg due to mild
urticaria. During PS, one patient had severe rhinitis and sneez-
ing after inhalation of 200μg budesonide. All patients made a
full recovery after stopping treatment. There were no serious 
adverse events during the study.
DISCUSSION
Previous studies have shown that preventative or prophylactic 
treatment with budesonide10 or other inhaled corticosteroids 
such as beclomethasone dipropionate" and fluticasone pro-
pionate18 is more effective if treatment is initiated at least 1 week
prior to allergen challenge. In this placebo-controlled study, an 
attempt was made to evaluate budesonide treatment given for 1 
month prior to the start of the pollen season. There were, how-
ever, practical difficulties in recruiting so many patients to the
study at one time. To allow for the variation in the pollen levels 
during the PPS treatment period, the results were calculated tak-
ing the daily pollen level of exposure for each individual patient 
into account in the analysis. This should give a more accurate
reflection of the true treatment efficacy in controlling symptoms. 
Patients who received placebo PPS (groups B and E) had scores 
for individual symptoms that were approximately twice those of 
the budesonide-treated groups. This would appear to indicate
that symptoms are already troublesome just before and very early 
on in the pollen season and would confirm the well-recognized 
nasal 'priming' effect of the first pollen exposure.19,20 The
200μgand 400μg doses of budesonide were both associated
with significant i rov ment in symptoms compared with the 
placebo, during PPS. The nasal symptoms experienced in the 
PPS were w ll-correlated with pollen levels and total symptom
scores were significantly lower during budesonide treatment at 
all pollen levels (Fig. 2). When patients were asked to assess 
their trea ment at the end of PPS, it was clear that those who had
received 400μg budesonide perceived significant benefit com-
pared with those on the placebo. The beneficial effect of budes-
onide on symptoms was particularly noticeable at higher pollen 
levels.
At the beginning of the pollen season itself, patients on
200μg of bud sonide were better controlled if they had been
pre-treated with budesonide 400μg PPS(group A)than those
pre-treated with 200μg PPS (group D). Otherwise, there were
no differences between 200μg and 400μg. Therefore, once
contr l of symptoms has been established with the 400μg dose
f budesonide PPS, it is possible to maintain the status quo dur-
ing the pollen season when the dose is reduced to 200μg.This
suggests that it is preferable to pre-treat with a full dose of 
inhaled corticosteroid in an attempt to stall the inflammatory 
process in its early stages and reduce the 'nasal priming' effect 
of the initial pollen challenge.
 Budesonide has previously been shown to reduce total symp-
tom scores at all levels of pollen exposure.21 It is interesting to 
note from our study that patients in group B, who had received
only placebo PPS, obtained good symptom control even at 
high pollen levels (>90grains/m3 air) during PS, while taking
400μg budesonide; perhaps because the highest pollen levels
did not coincide with the start of active treatment. However, the
same patients did not have good symptom control at levels of 
pollen above 10grains/m3 air while taking the placebo during
PPS. Thus, although the full dose of budesonide is highly effec-
tive even when initiated at the start of or during the pollen sea-
son, symptoms may be troublesome before the season is fully 
established.
 Topical corticosteroids are thought to have wide-ranging 
actions within the nose. They seem to act on all aspects of the 
nasal inflammatory response that have been studied.22 Their
ability to reduce or prevent the influx of inflammatory cells into 
the nasal mucosa in response to nasal challenge with pollen 
allergen has been demonstrated both under laboratory condi-
tions2,7 and during natural pollen exposure during the pollen
season.23,24 They also prevent allergen-induced release of medi-
ators from inflammatory cells25 and exudation of plasma and 
plasma-derived mediators from the nasal mucosa.26 Topical
budesonide therapy is considered to be one of the most effective 
inhaled corticosteroid treatments currently available for allergic
rhinitis, its efficacy exceeding that of antihistamines,27,28 sodium 
cromoglycate29 and immunotherapy.30
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In conclusion, we suggest that the most effective treatment
regimen to avoid the troublesome nasal symptoms resulting
from pollen allergy, is pre-treatment of patients about 4 weeks 
prior to, or early in, the pollen season with full-dose topical
nasal budesonide (400μg) or another corticosteroid. After this
initial treatment, most patients can be adequately controlled on
200μg budesonide for the duration of the pollen season.
ACKNOWLEDGMENTS
We wish to acknowledge the participation of the following prin-
cipal investigators in each study centre:
 Dr Antonio Miadonna, Istituto Clinica Medica II, Policlinico F. 
Sforza
 Dr Romano Zerboni, Allergologia e Immunologia Clinica, 
Nuova Ospedale San Giovanni di Dio
 Dr Luigi Andri, Servizio Autonamo di Allergologia, Istituti 
Ospedalieri
Dr Franco Cosmi, Servizio di Allergologia, Ospedale di Prato
 Dr Gemma Gherson, Servizio di Fisiopatologia Respiratoria, 
Ospedale Armanni Largo Trento
 Dr Sergio Bonini, Scuola di specializzazione in Allergologia e 
Immunologia, Clinica Universita di Napoli
 Dr Arsenio Corrado Negrini, Servizio Autonamo di Aller-
gologia, Ospedale San Martino
 Dr Franco Filiaci, Clinica ORL Policlinico, Umberto I Uni-
versita di Roma
 Dr Anna Teresa Loreti, Servizio di Fisiopatologia, Respiratoria 
Policlinico S. Orsola
  Dr Gennaro D'Amato, 36 Divisione di Pneumologia e 
Allergologia
 Dr Floriano Bonifazi, Servizio Autonamo di Allergologia, 
Respiratoria Ospedale Civile Umberto 1
 Dr Alfredo Tursi, Immunologia Clinica e Allergologia, Uni-
versity di Bani
 Dr Sergio Romagnani, Cattedra di Immunologia Clinica e 
Allergologia, University di Firenze
 Dr Franco Tigano, Istituto di Patologia Medica, University di 
Messina.
 We would also like to acknowledge Carole Caswell, MSc, for 
statistical analyses and Madeline Frame, PhD, for assistance with 
the manuscript. The study was sponsored by Astra Farmaceutici.
REFERENCES
1 Meltzer EO, Orgel HA, Bronsky EA et al. A dose-ranging study of
fluticasone propionate aqueous nasal spray for seasonal allergic 
rhinitis assessed by symptoms, rhinomanometry and nasal cytology. 
J. Allergy Clin. Immunol. 1990; 86:221-30.
2 Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ,
Lichtenstein LM. Basophil influx occurs after nasal antigen chal-
lenge: Effects of topical corticosteroid pretreatment. J. Allergy Clin. 
Immunol. 1988; 81: 580-9.
3 Bascom R, Pipkorn U, Lichtenstein LM, Naclerio RM. The influx of
inflammatory cells into nasal washings during the late response to
antigen challenge; effect of systemic steroid pretreatment. Am. 
Rev. Respir. Dis. 1988;138: 406-12.
4 Naclerio RM. Allergic rhinitis. N. Engl. J. Med. 1991; 325:
860-9.
5 Pipkorn U. Budesonide and nasal allergen challenge testing in
man. Allergy 1982; 37: 129-34.
6 Feather I, Peroni D, Wilson S, Smith S, Howarth P. Prophylactic flu-
ticasone propionate aqueous nasal spray (FP) suppresses 
eosinophil and mast cell accumulation in seasonal allergic rhinitis 
without altering T lymphocyte populations (abstract). J. Allergy 
Clin. Immunol. 1993; 91: 260.
7 Andersson M, Andersson P, Venge P, Pipkorn U. Eosinophils and
eosinophil cationic protein (ECP) in nasal lavages during allergen-
induced hyperresponsiveness. Effect of topical glucocorticosteroid 
treatment. Allergy 1989; 44: 342-8.
8 Pipkorn U. Effect of topical glucocorticoid treatment on nasal
mucosal mast cells in allergic rhinitis. Allergy 1983; 38: 125-9.
9 Konno A, Yamakoshi T, Terada N, Fulita Y. Mode of action of a
topical steroid on immediate phase reaction after antigen chal-
lenge and non-specific nasal hyperreactivity in nasal allergy. Int. 
Arch. Allergy Immunol. 1994; 103: 79-87.
10 Andersson M, Andersson P, Pipkorn U. Topical glucocortico-
steroids and allergen-induced increase in nasal reactivity: Rela-
tionship between treatment time and inhibitory effect. J. Allergy 
Clin. Immunol. 1988; 82: 1019-26.
11 Svensson C, Klementsson H, Alkner U, Pipkorn U, CGA Persson. A
topical glucocorticoid reduces the levels of fibrinogen and 
bradykinins on the allergic nasal mucosa during natural pollen 
exposure. J. Allergy Clin. Immunol. 1991; 87: 147.
12 Klementsson H, Svensson C, Andersson M, Venge P, Pipkorn U,
CGA Persson. Eosinophils, secretory responsiveness and gluco-
corticoid-induced effects on the allergic nasal mucosa during a 
weak pollen season. Clin. Exp. Allergy 1991; 21: 705-10.
13 The Italian Aeroallergen Network (Special issue). Aerobiologia
1990; 6 (2/1).
14 Pederson B, Larsen BB, Dahl R, Lindqvist N, Mygind N. Powder
administration of pure Budesonide for the treatment of seasonal 
allergic rhinitis. Allergy 1991; 46: 582-7.
15 Wilkinson P and Taudorf E. Clinical Trial of Hyposensitization in
Hay Fever: Two methods of relating symptom score to daily pollen 
counts. Allergy 1984; 39: 463-8.
16 Siegel S, Castellan NJ Jnr. Multiple comparison between treat-
ments. In: Anker JD ed. Nonparametric Statistics for the Behav-
ioural Science, 2nd edn. New York: McGraw-Hill, 1988; Ch. 8.
17 Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of
beclomethasone dipropionate aqueous nasal spray, astemizole 
and the combination in the prophylactic treatment of ragweed 
pollen-induced rhinoconlunctivitis. J. Allergy Clin. Immunol. 
1989; 83: 627-33.
18 Bousquet J, Chanal I, Alquie MC et al. Prevention of pollen rhinitis
symptoms: Comparison of fluticasone propionate aqueous nasal 
spray and disodium cromoglycate aqueous nasal spray. Allergy 
1993; 48: 327-33.
19 Connell JT. Quantitative intranasal challenges I. The priming
effect and its relationship to histopathological changes in nasal 
biopsies. J. Allergy 1968; 41: 101-10.
20 Connell JT. Quantitative intranasal pollen challenge II. Effect of
daily pollen challenge, environmental pollen exposure and placebo 
challenge in the nasal membrane. J. Allergy 1968, 41: 123-39.
21 Bhatia M, Campbell LM, Ross JR, Taylor MD, Peers EM,
Richardson PD. Intranasal budesonide once daily in seasonal 
allergic rhinitis. Curr. Med. Res. Opin. 1991; 12: 287-95.
22 Naclerio RM, Mygind N. Intranasal steroids-mechanism of
BUDESONIDE PRE-TREATMENT ALLERGIC RHINITIS 157
action. In: Mygind N, Naclerio RM, eds. Allergic and Non-Allergic 
Rhinitis-Clinical Aspects. 1993; Ch. 14.
23 Gomez E, Clague JE, Gatland D, Davies RJ. Effect of topical corti-
costeroids on seasonally induced increases in nasal mast cells. Br, 
Med. J. 1988; 296: 1572-3.
24 Otsuka H, Denburg JA, Befus AD et al. Effect of beclomethasone
dipropionate on nasal metachromatic cell sub-populations. Clin. 
Allergy 1986; 16: 589-97.
25 Lozewicz S, Wang J, Duddle J et al. Topical glucocorticoids inhibit
activation by allergen in the upper respiratory tract. J. Allergy Clin. 
Immunol. 1992; 89: 951-7.
26 Svensson C, Klementsson H, Andersson M, Pipkorn U, Alkner U,
Persson CGA. Glucocorticoid-induced attenuation of mucosal 
exudation of fibrinogen and bradykinins in seasonal allergic rhini-
tis. Allergy 1994; 49: 177-83.
27 Ramsdale EH, Kline PA. Comparison of an intranasal steroid
(budesonide) with terfenadine in the treatment of ragweed-
induced rhinoconjuctivitis. J. Allergy Clin. Immunol. 1990; 85 
(1 part 2): 244.
28 Bunnag C, Jareoncharsri P, Wong EC. A double-blind compari-
son of nasal budesonide and oral astemizole for the treatment of 
perennial rhinitis. Allergy 1992; 47: 313-17.
29 Bjerrum P, Illum P. Treatment of seasonal allergic rhinitis with
budesonide and disodium cromoglycate. Allergy 1985; 40: 65-9.
30 Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of
the efficacy and side-effects of aqueous steroid nasal spray 
(budesonide) and allergen-injection therapy (Pollinex-R) in the 
treatment of seasonal allergic rhinoconjunctivitis. J. Allergy Clin. 
Immunol. 1990; 85: 606-11.
